
    
      To assess whether vitamin D supplementation, in the follow up period after diagnosis and
      surgery of a first cutaneous malignant melanoma, has a protective effect on relapse of
      cutaneous malignant melanoma and whether this protective effect correlates with vitamin D
      levels in serum and vitamin D receptor (VDR) immunoreactivity in the primary tumor.
    
  